Trial Profile
Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- 16 Dec 2020 Status changed from active, no longer recruiting to completed.
- 28 Oct 2020 Results published in the Clinical Cancer Research
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium